Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
small-molecule TNF inhibitor
- Development stage
- Preclinical
- Lead developer
- Arcus Biosciences
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
The small-molecule TNF inhibitor is an investigational, orally bioavailable small-molecule inhibitor of tumor necrosis factor (TNF) being developed by Arcus Biosciences for the treatment of inflammatory and autoimmune diseases, including rheumatoid arthritis, psoriasis, and inflammatory bowel disease (such as ulcerative colitis). Unlike conventional anti-TNF biologics (such as adalimumab) that block both TNF receptor 1 (TNFR1) and TNF receptor 2 (TNFR2) signaling, this small-molecule inhibitor is designed to selectively block soluble TNF (sTNF)/TNFR1 signaling while preserving membrane TNF (mTNF)/TNFR2 signaling. Sparing TNFR2 signaling maintains regulatory T cell (Treg) stability and suppressive function and prevents pathogenic cytokine production (such as IFN-γ and IL-17) from helper T cells, potentially offering superior safety and efficacy. The program is expected to enter Phase 1 clinical trials in early 2027.
- Other names
- TNF small-molecule inhibitororal TNF inhibitororal small-molecule TNF inhibitor
02
Targets
TNFA (Tumor necrosis factor alpha (soluble))
Beyond the preview
Go deeper on small-molecule TNF inhibitor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on small-molecule TNF inhibitor.